Objectives
- Describe the epidemiology and mechanisms contributing to increased cardiovascular disease risk among people with HIV, including the effects of chronic inflammation, immune activation, and aging.
- Explain traditional and HIV-specific cardiovascular risk factors that may influence long-term health outcomes in people with HIV.
- Identify the impact of antiretroviral therapy, comorbid conditions, and social determinants of health on cardiovascular risk management in HIV care.
- Outline the results of the REPRIEVE trial on preventing cardiovascular disease in people with HIV.
- Describe interdisciplinary strategies to optimize cardiovascular risk reduction in people with HIV, including prevention, screening, lifestyle interventions, and pharmacologic management.
Agenda
Welcome/MAAETC Overview
Speaker Introductions
Presentation
Q&A
Event Wrap up
Speaker
Caitlin Prather, PharmD, BCACP, AAHIVP, TTS
Senior Clinical Pharmacist II, Juniper and PRIDE Clinics
Residency Program Director, PGY2 Ambulatory Care
